Published July 23, 2026
On August 4, 2025, DuPont, Chemours, and Corteva announced a combined $875 million settlement with the State of New Jersey, resolving a 2019 lawsuit and a wide range of related environmental claims tied to PFAS contamination at four industrial sites: Chambers Works, Parlin, Pompton Lakes Works, and Repauno. The payments are structured over 25 years, with Chemours responsible for 50% of the total, DuPont for roughly 35.5%, and Corteva covering the remainder.
Beyond the headline $875 million figure, the companies agreed to establish a remediation fund of up to $1.2 billion and a separate $475 million reserve fund designed to protect New Jersey taxpayers if any of the companies were to default on their obligations. New Jersey's attorney general's office valued the overall agreement — including the remediation and reserve commitments — at more than $2 billion, calling it the state's largest PFAS-related recovery to date. Payments under the settlement were set to begin no earlier than January 1, 2026.
This settlement didn't happen in isolation. It followed a separate $450 million agreement New Jersey reached with 3M in May 2025 over PFAS contamination at overlapping sites, and built on earlier state settlements with Solvay (about $393 million in 2023) and Arkema. Taken together, state officials have said New Jersey has recovered close to $3 billion in PFAS-related settlements since first filing suit in 2019 — one of the most extensive state-level PFAS recovery efforts in the country.
For residents near the affected sites, the practical impact of settlements like this one depends heavily on how remediation funds are actually deployed over the coming years — a process that, as of mid-2026, is still working through court approval and consent order procedures.
State settlements fund environmental cleanup, but they're separate from individual claims by people who developed health conditions after PFAS exposure through contaminated water. See Atumio's PFAS contamination lawsuit page for a free eligibility review, or start your case review directly.